Atrasentan Tied to Lower Risk for Kidney Events in T2DM With CKD
FRIDAY, April 19, 2019 -- Atrasentan is associated with a reduced risk for renal events in patients with type 2 diabetes and chronic kidney disease, according to a study published online April 14 in The Lancet to coincide with the International...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Chronic Kidney Disease | Diabetes | Diabetes Type 2 | Endocrinology | Pharmaceuticals | Study | Urology & Nephrology